

REMARKS

The above amendments correspond to the Brief Description of the Drawings to the panel numbering that was required for the formal drawings, and corrects errors in the descriptions thereof to correspond with the first paragraph of the Detailed Description, which discusses the results depicted in the Figures.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Nancy J. Axelrod

Atty. Reg. No. 44,014

Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Date: **April 15, 2002**

K:\Sch\1537D2\REPLY.doc

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

On page 14, lines 3-6, please replace the following paragraph:

Figure 1: Figure 1 shows the effects of L-NAME (NOS inhibitor) on implantation in rats. The animals were treated with 25 and 50 mg/animal/day L-NAME administered via continuous s.c. infusion from day 1 post coitum (p.c.) until day 7 p.c. The autopsy was performed on either day 9 (Fig. 1A) or 12 (Fig. 1B) p.c. and the diameter of the implantation sites were measured (Fig. 1C).

On Page 14, lines 7-10, please replace the following paragraph:

Figure 2: Figure ~~1~~ 2 shows the effects of L-NAME (NOS inhibitor) on implantation in rats. The animals were treated with 25 and 50 mg/animal/day L-NAME administered via continuous s.c. infusion on day 5-7 (p.c.). The autopsy was performed on ~~either day 9~~ on day 12 p.c. and the number of pathological implantation sites were counted (Fig. 2A), and their diameter (Fig. 2B) and weight (Fig. 2C) measured.